Max Hodak

1. Key Themes

The Brain as a Computer: A Framework That Unlocks Medicine's Hardest Problems

Max Hodak's foundational conviction is that treating the brain as a literal computer — not a metaphor — is what separates Science Corp from conventional biotech. This lens explains why device-based interventions produce dramatically faster and more reliable results than small molecules or biologics.

"The brain very literally, very clearly, plainly is a computer. You can solve computational problems by arranging matter in a certain way and then taking your hands off and pressing go... If I put electrodes in M1, you will probably be using a computer in an hour." 00:00:00

Device-Based Medicine Beats Drug Discovery on Speed and Predictability

Hodak makes a pointed argument that the engineering paradigm — with clear feedback loops and iterative improvement — systematically outperforms the random walk of drug discovery, where a decade of work can end with a binary "no" from a single clinical trial.

"You can do drug discovery for a decade, run a clinical trial. You're going to turn over a card. The answer might be no. And then like everybody goes home. Whereas here we have a clear sense of how to make the thing better." 00:08:04

Retinal Prosthetics as the First Commercial Proof Point for BCI

Prima has received CE mark approval in Europe and will begin commercial sales within weeks of the podcast recording. This is framed not just as a product milestone but as proof that the engineering approach to vision works — and that a clear upgrade path exists.

"Nobody had previously ever been able to restore a form vision image in the mind's eye of a blind patient in this way. But at the same time, it's a small field of view. It's like looking through a straw. It's only black and white. We need to add depth of grayscale. We think we see a path to get at least red and green." 00:00:27

The Platonic Representation Hypothesis: AI and Neuroscience Are Converging on the Same Truth

Hodak describes an empirically observable alignment between the internal representations of large AI models and neural recordings from animal brains. Science Corp uses this practically — it is not a theoretical curiosity but an operational tool.

"We know that that is true because we can get alignments between animal brain neural recordings and AI model internal representations. That was a big clue to me that AI was on the right track... There's some fact about the universe for these things as they're learning or grabbing onto some true underlying data manifold. It feels like a law of physics. Like if you apply enough compute to matter, you get this thing that looks like intelligence." 00:20:39

Substrate Independence as the True Long-Term Mission

The entire Science Corp pipeline — vision, biohybrid neural interfaces, perfusion medicine — points toward a single destination: making the human brain portable and resilient enough to survive the failure of the biological body that houses it.

"At the point where you achieve substrate independence, you can really take that almost anywhere you want, which is why that's really, really interesting... Swappable parts and substrate independence." 00:18:58

BCI Is a Category, Not a Bet — Most Investors Are Thinking About It Wrong

Hodak draws an analogy to pharma: making one BCI investment and calling it covered is as unsophisticated as making one drug investment. The range of approaches — EEG-based silent speech, implanted motor decoders, retinal prosthetics, biohybrid interfaces — represent completely different scientific hypotheses and company types.

"BCI is a category kind of like how pharma is a category. I think sometimes you talk to VCs like, oh, we have a BCI bet. Like, do you have a drug bet? You made one bet on a drug — is that how you think about the category?" 00:12:26

The 10-Bit-Per-Second Cognitive Bottleneck Limits Brain-Keyboard Products

Hodak argues that the "latent thoughts waiting to be transmitted faster" premise behind brain-keyboard products is probably wrong. Human cognition has a deeply evolved ~10 bits/second throughput ceiling that language already largely saturates, making high-bandwidth thought-to-AI interfaces less transformative than advertised.

"There's this 10 bit per second kind of famous cognitive bottleneck... There's like a bunch of different independent lines of evidence for this. So there's some deeply evolved cognitive bottleneck at about that. And I think that this kind of rolls up through language." 00:29:34

Consciousness Requires Continuity, Not Just Fidelity of Simulation

Hodak articulates a philosophical position with real downstream product implications: people will not find satisfaction in a perfect software copy of themselves if there is no phenomenal continuity. This shapes how Science Corp thinks about substrate independence — it must be a continuous transfer, not a scan-and-replicate process.

"If I just scanned your brain into a computer and there is a software simulation of you, is that — does that count as you? Like, would that make you feel better about dying of cancer?... I think that people are reticent to undergo general anesthesia, but they do it and they survive and they realize it's fine. And then there's, if I could make a copy of you and you can talk to that copy and you're like, okay, I will go away now. I just don't think that many people are going to be like, this is it." 00:16:05

Perfusion Medicine as the Underappreciated Third Pillar

While vision and biohybrid interfaces attract attention, Hodak mentions a program called Vessel in perfusion medicine as the third leg of the Science Corp pipeline. It is framed as part of the minimum set of programs required to drive a revolution in medicine over 10–15 years.

"There's three elements to our pipeline. The first is our work in vision. Second is our biohybrid neural interfaces. And the third is our work in a different area of medicine, perfusion, a program called Vessel. These three things together form kind of the minimum set of things that I think if they're successful on the time scale of 10 to 15 years could really drive, I think, a significant revolution in medicine broadly." 00:06:46

2. Contrarian Perspectives

The Brain-Computer Metaphor Is Not a Metaphor — It Is Literally True

Most neuroscientists and philosophers resist calling the brain a computer. Hodak insists this resistance is bike-shedding with no intellectual substance, and that the literal-computer framing is what enables the engineering approach that produces outsized results.

"I don't mean that metaphorically. The brain very literally, very clearly, plainly is a computer in my understanding of the world. I also view the universe generally as a computer... And so the fact that that unfolds in time to solve some computational problem, I think of that as a computer. The brain is the same thing. And I don't think there's necessarily a deeper point there." 00:00:00

Moonshots Have a Higher Success Rate Than Silicon Valley Mythology Suggests

The dominant VC framing of "moonshot" has been captured to mean "long odds, likely to fail, acceptable to burn investor capital." Hodak rejects this, pointing out that the actual Apollo program succeeded — and that using moonshot as an excuse for low expectations is intellectually dishonest.

"People forget that the moonshot worked. We left boot prints on the moon... It has gotten used in Silicon Valley to mean these things that have extremely long odds and are unlikely to work. And therefore, we can vaporize a bunch of investor money just fine. It's like, you know, when we went to the moon, we did it." 00:05:53

Brain-Keyboard / Faster-Thought-to-AI Products Are Probably Overhyped

Against the prevailing enthusiasm in BCI for communication-enhancement devices, Hodak argues that thoughts are not pre-formed and awaiting faster transmission — they are formed through the act of expression. The cognitive bottleneck is fundamental, not a technology gap.

"I think this idea that there's the stuff that's just preformed in your brain that if you could access it through BCI, it would be faster is probably not the case... It feels like you'll have it fully formed, but until you really sit down and try to write it out, it isn't really." 00:29:18

The Best Way to Do Neuroscience Right Now Is to Work on AI Models

Counterintuitively, Hodak argues that AI model internals are now a more tractable and fertile substrate for neuroscience research than biological brains — and that researchers who "left neuroscience" for AI labs may actually be doing more neuroscience than those who stayed.

"Ironically, it's probably working on AI... I have a couple of neuroscience friends at OpenAI and Anthropic who it's like, we joke, oh, you left neuroscience. Like, no, no, no. It is just way easier to do neuroscience on the models. But to the degree to which it is neuroscience is fascinating." 00:22:09

Cardiovascular Disease and Cancer Are Attackable Through BCI-Adjacent Approaches

Most people assume BCI addresses neurological conditions only. Hodak claims that cardiovascular disease and non-brain-metastatic cancer — the two leading causes of death — are also attackable through the Science Corp approach, framing the body's other organs as support infrastructure for the brain.

"The only organ that you can't even in principle transplant is the brain. The heart, the pancreas, the liver, the lungs, as far as I'm concerned, they're really support characters. They're there to keep the brain activity interesting and going... The two leading causes of death are cardiovascular disease and cancer not metastasized to the brain. And I think both of those are going to be really attackable through this type of work." 00:25:33

3. Companies Identified

Science Corp

Medical device company focused on vision restoration, biohybrid neural interfaces, and perfusion medicine. Founded by Max Hodak after his departure from Neuralink. The central company of the episode — its Prima retinal prosthesis just received CE mark approval in Europe and will begin commercial sales imminently. The company takes a tech-company approach to biology, raised predominantly from tech investors, and has a 10–15 year pipeline aimed at substrate independence and dramatically reduced human fragility.

"We use specifically an understanding of how to work with the brain to get big effect sizes that you don't get in medicine often. Our main product is a retinal prosthesis. You can think of it like a cochlear implant for the eye." 00:01:36

Pixium Vision

Small French medical device company that had developed the state-of-the-art electrical retinal stimulation technology (originally invented at Stanford) before being acquired by Science Corp in late 2022. The acquisition was described as a non-obvious opportunity that most observers missed.

"There was a company in France called Pixium that back in late 2022 had by far the state-of-the-art work. It was originally developed by an inventor at Stanford and then licensed to this small French company. And they were in the middle of clinical trials... And we got to know them over the course of a couple years. And then we're in a position to acquire them when we saw something that I think kind of nobody else really saw at the time." 00:04:54

Second Sight Medical Products

Early-generation retinal prosthesis company that received approval roughly a decade before the podcast. Referenced as a pricing precedent: despite inferior performance (no form vision, only flashes of light), they charged approximately $150,000 per patient in the mid-2010s, establishing a high pricing floor for the category.

"Second Sight 10 years ago, they had a retinal prosthesis that works differently than ours does. It did not get the type of performance that Prima does... They got paid about $150,000 per patient in the mid 2010s." 00:23:30

Neuralink

Elon Musk's brain-computer interface company, where Max Hodak was a co-founder before departing. Referenced as context for Hodak's background and the broader BCI field.

"Today, I'm here with Max Hodak, the founder and CEO of Science, formerly of Neuralink." 00:00:55

4. People Identified

Founder and CEO of Science Corp, formerly co-founder of Neuralink. Combines deep technical knowledge of neuroscience and BCI with a systems-level philosophical framework around consciousness, substrate independence, and the engineering approach to medicine. Identified throughout as the primary source of insight in the episode.

"We use specifically an understanding of how to work with the brain to get big effect sizes that you don't get in medicine often." 00:01:36

Bob Nelson

Biotech venture investor. Identified as the only VC Hodak specifically sought out for Science Corp's Series A — notable because Science Corp raised predominantly from tech investors, making Nelson the single exception Hodak considered worth pitching from the biotech investing world.

"There's only one VC that I sought out at all at the Series A that I went to go pitch, which was Bob Nelson, who's a biotech investor." 00:12:03

Laura Deming

Mentioned by Sarah Guo as someone who posed a pointed philosophical question about trading off identity characteristics under continuity — specifically whether one would accept a significantly degraded IQ in exchange for continuous experience. Deming is a well-known longevity-focused investor and thinker.

"Laura Deming asked me this." 00:18:54

5. Operating Insights

Acquire the Best-in-World Asset When No One Else Sees It

Science Corp's path to its flagship product was not internal invention but a targeted acquisition of Pixium Vision — a small, undercapitalized French company with the world's best electrical retinal stimulation technology, mid-trial, at a moment when no one else recognized its value. The two-year relationship-building prior to the acquisition was deliberate. This is a repeatable playbook: identify the best technical asset in a niche, build a relationship over years, and acquire when the window opens.

"We got to know them over the course of a couple years. And then we're in a position to acquire them when we saw something that I think kind of nobody else really saw at the time. And that deal has turned out to be great." 00:04:54

Structure a Pipeline With a Near-Term Business to Fund Long-Term Research

Hodak explicitly describes pairing the biohybrid neural interface research (long-horizon, high-risk) with a near-term commercial business in vision. Without the near-term anchor, the research program has no funding runway. This is a non-obvious structural discipline: the long-term moonshot requires a real business to sustain it.

"The bio-hybrid neural interface direction... is a big research project. It's very exciting research, but also needed to be paired with another near-term business. And we asked ourselves, like, what was the most valuable thing we could do?" 00:03:03

Use AI Model Internals as a Practical Tool in Neuroscience R&D

Science Corp is not merely theorizing about the Platonic representation hypothesis — they are using the alignment between AI model representations and animal neural recordings as a working laboratory instrument. This is an operational edge: using AI interpretability research to accelerate biological understanding.

"We use that constructively at science. We know that that is true because we can get alignments between animal brain neural recordings and AI model internal representations." 00:20:39

6. Overlooked Insights

An In-House Gene Therapy for the Retina Is Going to Humans Next Year

In a single sentence, Hodak mentions that Science Corp developed an indigenous gene therapy targeting the retina and expects it to enter human trials in the next year. This is entirely separate from the Prima electrical stimulation product and suggests a second, distinct clinical-stage program in vision that received almost no discussion time. Given that the only approved competing gene therapy reimburses at nearly $500,000 per eye despite modest efficacy, a superior in-house gene therapy could represent an enormous standalone business — yet it was dropped into the conversation as an aside.

"We developed indigenously a state-of-the-art gene therapy, which is probably going to humans next year." 00:04:28

Mouse Connectome Completion May Be Imminent — and Would Unlock the Entire Field

Hodak briefly flags that a complete mouse connectome may be achievable in the near term, and that this would be "enormously useful" for understanding overall brain architecture. This was a throwaway observation in a philosophical discussion about consciousness, but connectomics at the mouse scale would be a watershed scientific event — enabling the kind of mechanistic understanding that could accelerate every program in the BCI and neuroscience space, including Science Corp's own biohybrid interface research. No investor or public market currently prices this milestone.

"I think we're not that far from a mouse connectome. That would be enormously useful for facilitating this research and understanding about how all this works. We need to understand really basic questions, like what is the overall architecture of the brain?" 00:19:25